http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1817010-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e95b861c9a0185a42f811471302139aa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 |
| filingDate | 2005-11-22^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_499742992fb3fe9783f829164fecdd1d |
| publicationDate | 2007-08-15^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1817010-A2 |
| titleOfInvention | Controlled absorption of statins in the intestine |
| abstract | The present invention provides a controlled absorption formulation in which modified release of the active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than that can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, over which an outer coating is layered. The core is optionally and preferably in the form of a tablet. |
| priorityDate | 2004-11-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 500 of 500.